science

Teva Pharmaceutical’s SWOT analysis: stock navigates growth reset

SpaceX’s $20.7 Billion in 2025 CapEx Fueled by AI, Spacecraft

Lilly bets up to $202M in non-viral genetic medicines in Engage Bio buyout

SAN CARLOS, Calif.--(BUSINESS WIRE)--Engage Biologics Inc. (“Engage”), a preclinical biotechnology company pioneering non-viral DNA delivery, today announced that it has been acquired by Eli Lilly and Company (“Lilly”). Engage is developing the Tethosome platform, a novel non-viral DNA delivery syst

Lilly bets up to $202M in non-viral genetic medicines in Engage Bio buyout

The Bio-Pharma Industry and Society Listing Summary Please join the CSIS Global Health Policy Center on March 17, from 10:00am – 11:30am, for an exploration of how private bio-pharmaceutical firms can better support the critically important societal goals of improved affordability, access, quality,

A new study tries to put a number on the value of reliable numbers

Philip R. Lane: Climate change and monetary policy

York Space Systems to acquire Solestial

Trump said he is increasing the number of products on the platform by nearly seven times, adding more than 600 generic drugs to the site.